GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteostasis Therapeutics Inc (NAS:PTI) » Definitions » Volatility

Proteostasis Therapeutics (Proteostasis Therapeutics) Volatility : 220.51% (As of May. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Proteostasis Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-05), Proteostasis Therapeutics's Volatility is 220.51%.


Competitive Comparison of Proteostasis Therapeutics's Volatility

For the Biotechnology subindustry, Proteostasis Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteostasis Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteostasis Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Proteostasis Therapeutics's Volatility falls into.



Proteostasis Therapeutics  (NAS:PTI) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteostasis Therapeutics  (NAS:PTI) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Proteostasis Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Proteostasis Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteostasis Therapeutics (Proteostasis Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
80 Guest Street, Suite 500, 5th Floor, Boston, MA, USA, 02135
Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.
Executives
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Badrul A. Chowdhury director PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jeffrey W. Kelly director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Emmanuel Dulac director PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
David Arkowitz director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael Alfieri officer: Interim Head of Finance C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Greffrey S. Gilmartin officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Meenu Chhabra director, officer: President and CEO C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Sheila Wilson officer: Chief Operating Officer C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Benito Munoz officer: Chief Scientific Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Eric D Larson officer: See Remarks C/O NORTHERN POWER SYSTEMS CORP., 29 PITMAN ROAD, BARRE VT 05641
Marija Zecevic officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

Proteostasis Therapeutics (Proteostasis Therapeutics) Headlines

From GuruFocus